Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjogren's Syndrome-MedSci.cn

Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjogren's Syndrome

Hubbard, J; Campbell, K; Sivils, K; Hoffman, R; Lo, KH; Leu, J; Liva, S; Zuraw, Q; Stevens, A; Ling, L; Karcher, K; Ramchandren, S; Sun, H; Scofield, H; Wallace, D; Seror, R

ARTHRITIS & RHEUMATOLOGY, 2022; 74 (): 3999

科室
- - 订阅+
  - 更多科室
工具
服务